Global Interstitial Cystitis Drugs Market 2019-2023
About this market
The advent of gene therapy to drive market growth. Interstitial cystitis is characterized by urinary urgency and frequency, pelvic pain, and nocturia. However, only a few approved treatments are available, and curable treatments for the disease have not been identified yet. Although the etiology of the disease is not fully understood, usually, a bladder affected by interstitial cystitis is characterized by a thin and denuded urothelium. Most of the approved drugs and off-label drugs are small molecules, and they cannot completely cure the disease. Moreover, owing to the side effects and high costs of the available drugs, companies can establish new innovative treatment options such as regenerative therapy and gene therapy that have fewer side effects. Companies are also trying to develop a drug that can completely cure the disease. Technavio’s analysts have predicted that the interstitial cystitis drugs market will register a CAGR of almost 3% by 2023.
Increasing awareness of interstitial cystitis
Although interstitial cystitis is one of the significantly prevalent bladder diseases, many people are unaware of it as most of the symptoms are very similar to other bladder-related diseases. Hence, educating people and making them aware of interstitial cystitis are very important. Many government and non-government organizations are conducting various programs to increase the awareness of the disease.
Lack of approved drugs
The treatment of interstitial cystitis consists of oral therapy and intravesical therapy as the first- and second-line treatment options, respectively. However, no single treatment works for all people with the disease. The treatment is based on the symptoms of each patient. Most of the patients try different treatments (or combinations of treatments) to get rid of the symptoms. Currently, the global interstitial cystitis drugs market has only two approved drugs, ELMIRON and RIMSO-50 (dimethyl sulfoxide). These drugs are proven their efficacy over the symptomatic treatments. However, these drugs are expensive. Therefore, many patients use off-label drugs largely to relieve the symptoms of the disease.
For the detailed list of factors that will drive and challenge the growth of the interstitial cystitis drugs market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Mylan N.V and Pfizer the competitive environment is quite intense. Factors such as the increasing awareness of interstitial cystitis and the advent of gene therapy, will provide considerable growth opportunities to interstitial cystitis drugs manufactures. Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Mylan N.V, and Pfizer are some of the major companies covered in this report.
Technavio Announces the Publication of its Research Report – Global Interstitial Cystitis Drugs Market 2019-2023
Technavio recognizes the following companies as the key players in the global interstitial cystitis drugs market: Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Mylan N.V, and Pfizer.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the advent of gene therapy.”
According to the report, one of the major drivers for this market is the increasing awareness of interstitial cystitis.
Further, the report states that one of the major factors hindering the growth of this market is the lack of approved drugs.
Eli Lilly and Company
Johnson & Johnson Services
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook